An interventional study of Sleep Coach and Diabetes Education in Type 1 Diabetes, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 11 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Diabetes Mellitus, Type 1 by Vanderbilt University Medical Center — 5 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Vanderbilt University Medical Center.
Among the 15 studies in Diabetes Mellitus, Type 1 by Vanderbilt University Medical Center, this one is the 3rd largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2024, is one of 11 with no phase, and was the 12th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →5 of the 15 studies in Diabetes Mellitus, Type 1 by Vanderbilt University Medical Center are open now, in 1 country. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 13–21
Vanderbilt University Medical Center · Sites in United States
Ages 18–60 · Healthy volunteers
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Vanderbilt University Medical Center · Sites in United States
Ages 12–50
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 11 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 50 across the 14 interventional studies, 12 across the 1 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.
6 of the studies in Diabetes Mellitus, Type 1 by Vanderbilt University Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07116434Vanderbilt University Medical CenterDiscovery Diabetes | 2026-11 |
| NCT06852950Vanderbilt University Medical CenterContinuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge | 2027-01 |
| NCT05854069Vanderbilt University Medical CenterAdapting FAMS to Optimize CGM Use Among Emerging Adults With Type 1 Diabetes | 2027-01-31 |
| NCT06338553Vanderbilt University Medical CenterGLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab | 2027-03 |
| NCT06609356Vanderbilt University Medical CenterCardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 15 studies in Diabetes Mellitus, Type 1 by Vanderbilt University Medical Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this work is to conduct a randomized trial evaluating the effects of a behavioral intervention to increase sleep duration and quality for adolescents with type 1 diabetes (T1D). The impact of the sleep-promoting intervention on executive function and glycemic outcomes will be assessed. We will also explore multiple components of the recently identified central nervous system glymphatic system and evaluate how these components change and impact brain integrity and function with improved sleep.
This randomized controlled trial will assess whether a behavioral coaching intervention to improve sleep duration and quality in adolescents with type 1 diabetes will improve glucose control and executive function. We will recruit a sample of 150 adolescents with type 1 diabetes (T1D) and their caregivers at a single medical center. We plan to recruit equal numbers of boys and girls and over-enroll youth from minoritized racial and ethnic groups. After obtaining informed consent/assent and baseline data, we will randomize adolescents to the Sleep Coach condition (n=75) or the Enhanced Usual Care condition (n=75). Randomization will be computerized, and adolescents will be stratified by diabetes device use (insulin pumps, continuous glucose monitors) and age (11-14 years vs. 15-17 years). Adolescents and caregivers will complete survey measures again at 3 months, 6 months, and 12 months during regularly scheduled clinic visits. Adolescents will complete the NIH Toolbox measures of executive function at each study visit. Adolescents will be asked to wear a FitBit watch to assess sleep and complete sleep diaries at baseline and 3 months.
Participants randomized to the Sleep Coach group will be sent a binder with intervention materials for the 4 sessions. They will schedule individual phone calls with a trained member of the research team at a convenient time. The first call is expected to last 20-30 minutes, and the other calls are expected to last 10-15 minutes. Caregivers will receive an overview of the sleep intervention content, and they will be asked to support adolescents' attempts to change sleep habits.
Adolescents randomized to Enhanced Usual Care will receive diabetes education materials developed by our team for adolescents with T1D (based on publicly available materials on diabetes.org). Printed materials will be sent via mail and content will be shared via smart phone messages on the same schedule as participants randomized to the Sleep Coach intervention.
A representative group of 50 of the 150 adolescents in the study will be invited to participate in an additional study visit prior to the intervention to obtain magnetic resonance imaging (MRI) of the brain. Adolescents who agree to complete MRI of the brain will be asked to complete a follow-up visit approximately 6 months after the baseline visit, following the same protocol, and they will complete the daily sleep diary questions and share sleep data for another week.
Inclusion Criteria:
Exclusion Criteria:
Inclusion criteria for caregivers:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individualized sleep-promoting program for adolescents with type 1 diabetes
Behavioral: Sleep Coach
Educational Materials
Behavioral: Diabetes Education
Sleep-promoting intervention consisting of 4 phone sessions to improve sleep duration and consistency.
Participants will receive a a binder with educational information about diabetes and educational messages from the study team.
Sleep Duration
Total Sleep Time (average minutes per night) measured with Fitbit over 7 nights
Time frame: 3 months
Sleep Variability
Individual difference in sleep duration (minutes) measured with Fitbit over 7 nights
Time frame: 3 months
Executive Function BRIEF2
Behavior Rating Inventory of Executive Function 2nd Edition: 63-item measure, completed by parents to assess adolescent executive function in their daily life. Higher Global Executive Composite score indicates better executive function.
Time frame: 12 months
NIH Toolbox Dimensional Card Sort Test
Dimensional Change Card Sort Test takes 4 minutes for adolescents to complete on an iPad, assesses inhibition, a component of executive function
Time frame: 12 months
NIH Toolbox List Sorting Working Memory Test
List Sorting Working Memory takes 8-10 minutes for adolescents to complete on an iPad, assesses working memory, a component of executive function
Time frame: 12 months
Diabetes Management - Adolescent Report
Self-Care Inventory-Short Form: 9-item measure, assesses key components of adolescent diabetes management. Higher mean scores indicate better diabetes self-care.
Time frame: 12 months
Diabetes Management - Parent Report
Self-Care Inventory-Short Form: 9-item measure, assesses key components of adolescent diabetes management. Higher mean scores indicate better diabetes self-care.
Time frame: 12 months
Sleep Quality
Pittsburgh Sleep Quality Index (PSQI): 21-item measure completed by adolescents, assesses sleep quality. Higher scores indicate poorer sleep quality.
Time frame: 12 months
Hemoglobin A1C
An indicator of average blood glucose levels. HbA1c is collected as part of usual care and will be extracted from adolescents' medical records
Time frame: 12 months
Time in Range
Blood glucose levels, measured with continuous glucose monitors, that are within the target range (70-180 mg/dL) over 14 days. Time in Range is reported as a percentage and higher levels indicate better glycemic control.
Time frame: 12 months
Magnetic Resonance Imaging (MRI) of Brain: Glymphatic Flow
Fluid motion along perivascular spaces is assessed from MRI of the brian
Time frame: 6 months
Fractional Anisotropy from MRI of the Brain
Fractional anisotropy is calculated from diffusion tensor imaging MRI. Higher FA is associated with better white matter integrity in the brain
Time frame: 6 months
Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 36 months after the start.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 36 months is above that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanderbilt University Medical Center →